Today NICE, England published final draft guidance recommending Ixekizumab for treating moderate to severe plaque psoriasis. The draft guidance can be found here Ixekizumab is recommended as an option for treating plaque psoriasis in adults, only if: the disease is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or…
Our projects
Recent projects
